Search in:

Cell Cycle Volume 11, 2012 - Issue 18

Submit an article Journal homepage

Open access

1,254

Views

CrossRef citations to date

Altmetric

Editorials: Cell Cycle Features

A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies

Fubin Li Laboratory of Molecular Genetics and Immunology; The Rockefeller University; New York, NY USA

Jeffrey V. Ravetch Laboratory of Molecular Genetics and Immunology; The Rockefeller University; New York, NY USACorrespondence[email protected]

Pages 3343-3344 | Published online: 23 Aug 2012

Cite this article
https://doi.org/10.4161/cc.21842

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (27)

Judith Leitner, Ricarda Egerer, Petra Waidhofer-Söllner, Katharina Grabmeier-Pfistershammer & Peter Steinberger. (2023) FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab. Frontiers in Immunology 14.
Crossref

Sameer Quazi. (2022) TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy. Medical Oncology 39:12.
Crossref

Christopher S. Garris, Jeffrey L. Wong, Jeffrey V. Ravetch & David A. Knorr. (2021) Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Science Translational Medicine 13:594.
Crossref

Jordana Griffiths, Khiyam Hussain, Hannah L Smith, Theodore Sanders, Kerry L Cox, Monika Semmrich, Linda Mårtensson, Jinny Kim, Tatyana Inzhelevskaya, Chris A Penfold, Alison L Tutt, C Ian Mockridge, HT Claude Chan, Vikki English, Ruth F French, Ingrid Teige, Aymen Al-Shamkhani, Martin J Glennie, Bjorn L Frendeus, Jane E Willoughby & Mark S Cragg. (2020) Domain binding and isotype dictate the activity of anti-human OX40 antibodies. Journal for ImmunoTherapy of Cancer 8:2, pages e001557.
Crossref

Joshua T. Gamse, Wendy Freebern, Rashade Haynes II, Frank Simutis, Mary Pazian, James Crona, Helen G. Haggerty, Michael Graziano & Roderick Todd Bunch. (2020) Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody. Toxicology and Applied Pharmacology 409, pages 115285.
Crossref

David M. Richards, Viola Marschall, Katharina Billian-Frey, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Julian P. Sefrin, Matthias Schröder, Jaromir Sykora, Harald Fricke, Oliver Hill, Christian Gieffers & Meinolf Thiemann. (2019) HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality. Journal for ImmunoTherapy of Cancer 7:1.
Crossref

Xiaobo Liu, Yingjie Zhao, Huan Shi, Yan Zhang, Xueying Yin, Mingdong Liu, Huihui Zhang, Yongning He, Boxun Lu, Tengchuan Jin & Fubin Li. (2019) Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nature Communications 10:1.
Crossref

Sarah L. Buchan, Lang Dou, Marcus Remer, Steven G. Booth, Stuart N. Dunn, Chester Lai, Monika Semmrich, Ingrid Teige, Linda Mårtensson, Christine A. Penfold, H.T. Claude Chan, Jane E. Willoughby, C. Ian Mockridge, Lekh N. Dahal, Kirstie L.S. Cleary, Sonya James, Anne Rogel, Päivi Kannisto, Mats Jernetz, Emily L. Williams, Eugene Healy, J. Sjef Verbeek, Peter W.M. Johnson, Björn Frendéus, Mark S. Cragg, Martin J. Glennie, Juliet C. Gray, Aymen Al-Shamkhani & Stephen A. Beers. (2018) Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. Immunity 49:5, pages 958-970.e7.
Crossref

Christopher Paluch, Ana Mafalda Santos, Consuelo Anzilotti, Richard J. Cornall & Simon J. Davis. (2018) Immune Checkpoints as Therapeutic Targets in Autoimmunity. Frontiers in Immunology 9.
Crossref

Meinolf Thiemann, David M. Richards, Karl Heinonen, Michael Kluge, Viola Marschall, Christian Merz, Mauricio Redondo Müller, Tim Schnyder, Julian P. Sefrin, Jaromir Sykora, Harald Fricke, Christian Gieffers & Oliver Hill. (2018) A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity. Frontiers in Oncology 8.
Crossref

Concepción Camarero Bullón & Laura García Juan. (2018) Geografía histórica de los espacios reales: Alóndiga, Aceca y Barciles, despoblados del rey en la vega del Tajo. Estudios Geográficos 79:284, pages 209.
Crossref

Stylianos BournazosTaia T. WangRony DahanJad MaamaryJeffrey V. Ravetch. (2017) Signaling by Antibodies: Recent Progress. Annual Review of Immunology 35:1, pages 285-311.
Crossref

Di Zhang, Monica V. Goldberg & Mark L. Chiu. (2016) Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. Journal of Biological Chemistry 291:53, pages 27134-27146.
Crossref

Geoffrey S. Williams, Bina Mistry, Sandrine Guillard, Jane Coates Ulrichsen, Alan M. Sandercock, Jun Wang, Andrea González-Muñoz, Julie Parmentier, Chelsea Black, Jo Soden, Jim Freeth, Jelena Jovanović, Rebecca Leyland, Rafia S. Al-Lamki, Andrew J. Leishman, Steven J. Rust, Ross Stewart, Lutz Jermutus, John R. Bradley, Vahe Bedian, Viia Valge-Archer, Ralph Minter & Robert W. Wilkinson. (2016) Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget 7:42, pages 68278-68291.
Crossref

Marije B. Overdijk, J. H. Marco Jansen, Maaike Nederend, Jeroen J. Lammerts van Bueren, Richard W. J. Groen, Paul W. H. I. Parren, Jeanette H. W. Leusen & Peter Boross. (2016) The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking. The Journal of Immunology 197:3, pages 807-813.
Crossref

Rony Dahan, Bryan C. Barnhart, Fubin Li, Aaron P. Yamniuk, Alan J. Korman & Jeffrey V. Ravetch. (2016) Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell 29:6, pages 820-831.
Crossref

Sandrine Aspeslagh, Sophie Postel-Vinay, Sylvie Rusakiewicz, Jean-Charles Soria, Laurence Zitvogel & Aurélien Marabelle. (2016) Rationale for anti-OX40 cancer immunotherapy. European Journal of Cancer 52, pages 50-66.
Crossref

S. Vessillier, D. Eastwood, B. Fox, J. Sathish, S. Sethu, T. Dougall, S.J. Thorpe, R. Thorpe & R. Stebbings. (2015) Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. Journal of Immunological Methods 424, pages 43-52.
Crossref

Rony Dahan, Emanuela Sega, John Engelhardt, Mark Selby, Alan J. Korman & Jeffrey V. Ravetch. (2015) FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell 28:3, pages 285-295.
Crossref

David J. DiLillo & Jeffrey V. Ravetch. (2015) Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunology Research 3:7, pages 704-713.
Crossref

Randall J. Brezski. 2015. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies 125 146 .

Andrew Pincetic, Stylianos Bournazos, David J DiLillo, Jad Maamary, Taia T Wang, Rony Dahan, Benjamin-Maximillian Fiebiger & Jeffrey V Ravetch. (2014) Type I and type II Fc receptors regulate innate and adaptive immunity. Nature Immunology 15:8, pages 707-716.
Crossref

Fubin Li, Patrick Smith & Jeffrey V. Ravetch. (2014) Inhibitory Fcγ Receptor Is Required for the Maintenance of Tolerance through Distinct Mechanisms. The Journal of Immunology 192:7, pages 3021-3028.
Crossref

Martin Guilliams, Pierre Bruhns, Yvan Saeys, Hamida Hammad & Bart N. Lambrecht. (2014) The function of Fcγ receptors in dendritic cells and macrophages. Nature Reviews Immunology 14:2, pages 94-108.
Crossref

Fubin Li & Jeffrey V. Ravetch. (2013) Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proceedings of the National Academy of Sciences 110:48, pages 19501-19506.
Crossref

Yannick Bulliard, Rose Jolicoeur, Maurice Windman, Sarah M. Rue, Seth Ettenberg, Deborah A. Knee, Nicholas S. Wilson, Glenn Dranoff & Jennifer L. Brogdon. (2013) Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. Journal of Experimental Medicine 210:9, pages 1685-1693.
Crossref

Fabian Richter, Timo Liebig, Eric Guenzi, Andreas Herrmann, Peter Scheurich, Klaus Pfizenmaier & Roland E. Kontermann. (2013) Antagonistic TNF Receptor One-Specific Antibody (ATROSAB): Receptor Binding and In Vitro Bioactivity. PLoS ONE 8:8, pages e72156.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies

Articles from other publishers (27)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies

Citations (27)

Articles from other publishers (27)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date